Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 621

1.

Generating EQ-5D-3L Utility Scores from the Dermatology Life Quality Index: A Mapping Study in Patients with Psoriasis.

Davison NJ, Thompson AJ, Turner AJ, Longworth L, McElhone K, Griffiths CEM, Payne K; BADBIR Study Group.

Value Health. 2018 Aug;21(8):1010-1018. doi: 10.1016/j.jval.2017.10.024. Epub 2017 Dec 26.

PMID:
30098665
2.

Infliximab is associated with an increased risk of serious infection in patients with psoriasis in the United Kingdom and Republic of Ireland: results from the British Association of Dermatologists Biologic Interventions Register (BADBIR).

Yiu ZZN, Ashcroft DM, Evans I, McElhone K, Lunt M, Smith CH, Walton S, Murphy R, Reynolds NJ, Ormerod AD, Griffiths CEM, Warren RB; BADBIR Study Group.

Br J Dermatol. 2018 Aug 2. doi: 10.1111/bjd.17036. [Epub ahead of print]

PMID:
30070708
3.

Clinical and genetic differences between pustular psoriasis subtypes.

Twelves S, Mostafa A, Dand N, Burri E, Farkas K, Wilson R, Cooper HL, Irvine AD, Oon HH, Kingo K, Köks S, Mrowietz U, Puig L, Reynolds N, Tan ES, Tanew A, Torz K, Trattner H, Valentine M, Wahie S, Warren RB, Wright A, Bata-Csörgő Z, Szell M, Griffiths CEM, Burden AD, Choon SE, Smith CH, Barker JN, Navarini AA, Capon F.

J Allergy Clin Immunol. 2018 Jul 21. pii: S0091-6749(18)31039-X. doi: 10.1016/j.jaci.2018.06.038. [Epub ahead of print]

4.

A framework for multi-omic prediction of treatment response to biologic therapy for psoriasis.

Foulkes AC, Watson DS, Carr DF, Kenny JG, Slidel T, Parslew R, Pirmohamed M; PSORT Consortium, Anders S, Reynolds NJ, Griffiths CEM, Warren RB, Barnes MR.

J Invest Dermatol. 2018 Jul 17. pii: S0022-202X(18)32355-8. doi: 10.1016/j.jid.2018.04.041. [Epub ahead of print]

PMID:
30030151
5.

Psychiatric morbidity and suicidal behaviour in psoriasis: a primary care cohort study.

Parisi R, Webb RT, Kleyn CE, Carr MJ, Kapur N, Griffiths CEM, Ashcroft DM.

Br J Dermatol. 2018 Jul 14. doi: 10.1111/bjd.17004. [Epub ahead of print]

PMID:
30007069
6.

Ixekizumab provides superior efficacy compared to ustekinumab over 52-weeks of treatment: results from IXORA-S, a phase 3 study.

Paul C, Griffiths CEM, van de Kerkhof PCM, Puig L, Dutronc Y, Henneges C, Dossenbach M, Hollister K, Reich K.

J Am Acad Dermatol. 2018 Jun 30. pii: S0190-9622(18)32195-9. doi: 10.1016/j.jaad.2018.06.039. [Epub ahead of print]

PMID:
29969700
7.

Greater improvement in quality of life outcomes in patients using fixed-combination calcipotriol plus betamethasone dipropionate aerosol foam versus gel: results from the PSO-ABLE study.

Griffiths CE, Stein Gold L, Cambazard F, Kalb RE, Lowson D, Møller A, Paul C.

Eur J Dermatol. 2018 Jun 1;28(3):356-363. doi: 10.1684/ejd.2018.3302.

PMID:
29952297
8.

Keratinocytes derived from late-onset psoriasis skin do not impair Langerhans cell migration.

Eaton LH, Dearman RJ, Kimber I, Griffiths CEM.

Br J Dermatol. 2018 Jun 19. doi: 10.1111/bjd.16896. [Epub ahead of print]

PMID:
29923325
9.

What's new in psoriasis treatment? An analysis of systematic reviews published in 2015.

Foulkes AC, Ferguson F, Grindlay DJC, Williams HC, Griffiths CEM, Warren RB.

Clin Exp Dermatol. 2018 May 27. doi: 10.1111/ced.13601. [Epub ahead of print] Review.

PMID:
29806111
10.

Efficacy of Guselkumab Compared With Adalimumab and Placebo for Psoriasis in Specific Body Regions: A Secondary Analysis of 2 Randomized Clinical Trials.

Foley P, Gordon K, Griffiths CEM, Wasfi Y, Randazzo B, Song M, Li S, Shen YK, Blauvelt A.

JAMA Dermatol. 2018 Jun 1;154(6):676-683. doi: 10.1001/jamadermatol.2018.0793.

PMID:
29799960
11.

Langerhans cells express human beta defensin-3: relevance for immunity during skin ageing.

Pilkington SM, Dearman RJ, Kimber I, Griffiths CEM.

Br J Dermatol. 2018 May 14. doi: 10.1111/bjd.16770. [Epub ahead of print]

PMID:
29758092
12.

Cumulative exposure to biological therapy and risk of cancer in patients with psoriasis: a meta-analysis of Psonet studies from Israel, Italy, Spain, the U.K. and Republic of Ireland.

Garcia-Doval I, Descalzo MA, Mason KJ, Cohen AD, Ormerod AD, Gómez-García FJ, Cazzaniga S, Feldhamer I, Ali H, Herrera-Acosta E, Griffiths CEM, Stern RS, Naldi L; Psonet Network.

Br J Dermatol. 2018 May 3. doi: 10.1111/bjd.16715. [Epub ahead of print]

PMID:
29723914
13.

Lipidomics for translational skin research: A primer for the uninitiated.

Kendall AC, Koszyczarek MM, Jones EA, Hart PJ, Towers M, Griffiths CEM, Morris M, Nicolaou A.

Exp Dermatol. 2018 Jul;27(7):721-728. doi: 10.1111/exd.13558. Epub 2018 May 7. Review.

PMID:
29654617
14.

Dual neutralization of both interleukin 17A and interleukin 17F with bimekizumab in patients with psoriasis: Results from BE ABLE 1, a 12-week randomized, double-blinded, placebo-controlled phase 2b trial.

Papp KA, Merola JF, Gottlieb AB, Griffiths CEM, Cross N, Peterson L, Cioffi C, Blauvelt A.

J Am Acad Dermatol. 2018 Aug;79(2):277-286.e10. doi: 10.1016/j.jaad.2018.03.037. Epub 2018 Mar 30.

15.

Correction to: Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders: A Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and -3).

Blauvelt A, Papp KA, Griffiths CEM, Puig L, Weisman J, Dutronc Y, Kerr LF, Ilo D, Mallbris L, Augustin M.

Am J Clin Dermatol. 2018 Jun;19(3):457. doi: 10.1007/s40257-018-0353-x.

16.

Comparison of Drug Discontinuation, Effectiveness, and Safety Between Clinical Trial Eligible and Ineligible Patients in BADBIR.

Mason KJ, Barker JNWN, Smith CH, Hampton PJ, Lunt M, McElhone K, Warren RB, Yiu ZZN, Griffiths CEM, Burden AD; BADBIR Study Group.

JAMA Dermatol. 2018 May 1;154(5):581-588. doi: 10.1001/jamadermatol.2018.0183.

PMID:
29590279
17.

Patient-dermatologist agreement in psoriasis severity, symptoms and satisfaction: results from a real-world multinational survey.

Griffiths CEM, Augustin M, Naldi L, Romiti R, Guevara-Sangines E, Howe T, Pietri G, Gilloteau I, Richardson C, Tian H, Jo SJ.

J Eur Acad Dermatol Venereol. 2018 Mar 10. doi: 10.1111/jdv.14937. [Epub ahead of print]

PMID:
29524271
18.

Patient-reported symptoms and signs of moderate-to-severe psoriasis treated with guselkumab or adalimumab: results from the randomized VOYAGE 1 trial.

Papp KA, Blauvelt A, Kimball AB, Han C, Randazzo B, Wasfi Y, Shen YK, Li S, Griffiths CEM.

J Eur Acad Dermatol Venereol. 2018 Mar 6. doi: 10.1111/jdv.14910. [Epub ahead of print]

PMID:
29512196
19.

Structural and compositional diversity of fibrillin microfibrils in human tissues.

Eckersley A, Mellody KT, Pilkington S, Griffiths CEM, Watson REB, O'Cualain R, Baldock C, Knight D, Sherratt MJ.

J Biol Chem. 2018 Apr 6;293(14):5117-5133. doi: 10.1074/jbc.RA117.001483. Epub 2018 Feb 16.

20.

Acute psychosocial stress downregulates N-methyl-d-aspartate receptors in healthy human skin.

Hunter HJA, Morsman E, Mellody KT, Ogden SK, Zeef LAH, Hayes A, Griffiths CEM, Kleyn CE.

Br J Dermatol. 2018 Jun;178(6):1458-1459. doi: 10.1111/bjd.16466. Epub 2018 May 9. No abstract available.

PMID:
29451693
21.

Does message framing affect changes in behavioural intentions in people with psoriasis? A randomized exploratory study examining health risk communication.

Keyworth C, Nelson PA, Bundy C, Pye SR, Griffiths CEM, Cordingley L.

Psychol Health Med. 2018 Aug;23(7):763-778. doi: 10.1080/13548506.2018.1427876. Epub 2018 Jan 30.

PMID:
29380626
22.

Differential effects of secukinumab vs. ustekinumab for treatment of psoriasis on quality of life, work productivity and activity impairment: a structural equation modelling analysis.

Stull DE, Griffiths CEM, Gilloteau I, Zhao Y, Guana A, Finlay AY, Sherif B, Houghton K, Puig L.

Br J Dermatol. 2018 Jun;178(6):1297-1307. doi: 10.1111/bjd.16366. Epub 2018 Apr 14.

PMID:
29355896
23.

A photonumeric scale for the assessment of atrophic facial photodamage.

Ayer J, Ahmed A, Duncan-Parry E, Beck P, Griffiths TW, Watson REB, Griffiths CEM.

Br J Dermatol. 2018 May;178(5):1190-1195. doi: 10.1111/bjd.16331. Epub 2018 Mar 30.

PMID:
29333668
24.

A multidimensional assessment of the burden of psoriasis: results from a multinational dermatologist and patient survey.

Griffiths CEM, Jo SJ, Naldi L, Romiti R, Guevara-Sangines E, Howe T, Pietri G, Gilloteau I, Richardson C, Tian H, Augustin M.

Br J Dermatol. 2018 Jan 12. doi: 10.1111/bjd.16332. [Epub ahead of print]

PMID:
29328510
25.

Defining tissue proteomes by systematic literature review.

Hibbert SA, Ozols M, Griffiths CEM, Watson REB, Bell M, Sherratt MJ.

Sci Rep. 2018 Jan 11;8(1):546. doi: 10.1038/s41598-017-18699-8.

26.

Impaired Langerhans cell migration in psoriasis is due to an altered keratinocyte phenotype induced by interleukin-17.

Eaton LH, Mellody KT, Pilkington SM, Dearman RJ, Kimber I, Griffiths CEM.

Br J Dermatol. 2018 Jun;178(6):1364-1372. doi: 10.1111/bjd.16172. Epub 2018 Mar 31.

PMID:
29194565
27.

Intentional and Unintentional Medication Non-Adherence in Psoriasis: The Role of Patients' Medication Beliefs and Habit Strength.

Thorneloe RJ, Griffiths CEM, Emsley R, Ashcroft DM, Cordingley L; British Association of Dermatologists Biologic Interventions Register; Psoriasis Stratification to Optimise Relevant Therapy Study Groups.

J Invest Dermatol. 2018 Apr;138(4):785-794. doi: 10.1016/j.jid.2017.11.015. Epub 2017 Nov 26.

28.

Differential Drug Survival of Second-Line Biologic Therapies in Patients with Psoriasis: Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR).

Iskandar IYK, Warren RB, Lunt M, Mason KJ, Evans I, McElhone K, Smith CH, Reynolds NJ, Ashcroft DM, Griffiths CEM; BADBIR Study Group.

J Invest Dermatol. 2018 Apr;138(4):775-784. doi: 10.1016/j.jid.2017.09.044. Epub 2017 Dec 6.

29.

The role of the microbiome in psoriasis: moving from disease description to treatment selection?

Langan EA, Griffiths CEM, Solbach W, Knobloch JK, Zillikens D, Thaçi D.

Br J Dermatol. 2018 May;178(5):1020-1027. doi: 10.1111/bjd.16081. Epub 2018 Mar 6. Review.

PMID:
29071712
30.

Risk of Serious Infection in Patients with Psoriasis Receiving Biologic Therapies: A Prospective Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR).

Yiu ZZN, Smith CH, Ashcroft DM, Lunt M, Walton S, Murphy R, Reynolds NJ, Ormerod AD, Griffiths CEM, Warren RB; BADBIR Study Group.

J Invest Dermatol. 2018 Mar;138(3):534-541. doi: 10.1016/j.jid.2017.10.005. Epub 2017 Oct 17.

31.

Feeding filaggrin: effects of l-histidine supplementation in atopic dermatitis.

Tan SP, Brown SB, Griffiths CE, Weller RB, Gibbs NK.

Clin Cosmet Investig Dermatol. 2017 Oct 5;10:403-411. doi: 10.2147/CCID.S146760. eCollection 2017.

32.

Ixekizumab treatment for psoriasis: integrated efficacy analysis of three double-blinded, controlled studies (UNCOVER-1, UNCOVER-2, UNCOVER-3).

Papp KA, Leonardi CL, Blauvelt A, Reich K, Korman NJ, Ohtsuki M, Paul C, Ball S, Cameron GS, Erickson J, Zhang L, Mallbris L, Griffiths CEM.

Br J Dermatol. 2018 Mar;178(3):674-681. doi: 10.1111/bjd.16050. Epub 2018 Feb 23.

PMID:
28991370
33.

Reply to 'Impact of biologic therapies on risk of major adverse cardiovascular events in patients with psoriasis: systematic review and meta-analysis of randomized controlled trials': reply from the authors.

Rungapiromnan W, Yiu ZZN, Warren RB, Griffiths CEM, Ashcroft DM.

Br J Dermatol. 2017 Dec;177(6):1766-1767. doi: 10.1111/bjd.16043. Epub 2017 Nov 22. No abstract available.

PMID:
28990164
34.

Exome-wide association study reveals novel psoriasis susceptibility locus at TNFSF15 and rare protective alleles in genes contributing to type I IFN signalling.

Dand N, Mucha S, Tsoi LC, Mahil SK, Stuart PE, Arnold A, Baurecht H, Burden AD, Callis Duffin K, Chandran V, Curtis CJ, Das S, Ellinghaus D, Ellinghaus E, Enerback C, Esko T, Gladman DD, Griffiths CEM, Gudjonsson JE, Hoffman P, Homuth G, Hüffmeier U, Krueger GG, Laudes M, Lee SH, Lieb W, Lim HW, Löhr S, Mrowietz U, Müller-Nurayid M, Nöthen M, Peters A, Rahman P, Reis A, Reynolds NJ, Rodriguez E, Schmidt CO, Spain SL, Strauch K, Tejasvi T, Voorhees JJ, Warren RB, Weichenthal M, Weidinger S, Zawistowski M, Nair RP, Capon F, Smith CH, Trembath RC, Abecasis GR, Elder JT, Franke A, Simpson MA, Barker JN.

Hum Mol Genet. 2017 Nov 1;26(21):4301-4313. doi: 10.1093/hmg/ddx328.

35.

Multiple switches between GP2015, an etanercept biosimilar, with originator product do not impact efficacy, safety and immunogenicity in patients with chronic plaque-type psoriasis: 30-week results from the phase 3, confirmatory EGALITY study.

Gerdes S, Thaçi D, Griffiths CEM, Arenberger P, Poetzl J, Wuerth G, Afonso M, Woehling H.

J Eur Acad Dermatol Venereol. 2018 Mar;32(3):420-427. doi: 10.1111/jdv.14605. Epub 2017 Nov 2.

36.

Efficacy of guselkumab in subpopulations of patients with moderate-to-severe plaque psoriasis: a pooled analysis of the phase III VOYAGE 1 and VOYAGE 2 studies.

Gordon KB, Blauvelt A, Foley P, Song M, Wasfi Y, Randazzo B, Shen YK, You Y, Griffiths CEM.

Br J Dermatol. 2018 Jan;178(1):132-139. doi: 10.1111/bjd.16008. Epub 2017 Dec 14.

PMID:
28940259
37.

Alcohol-Related Mortality in Patients With Psoriasis: A Population-Based Cohort Study.

Parisi R, Webb RT, Carr MJ, Moriarty KJ, Kleyn CE, Griffiths CEM, Ashcroft DM.

JAMA Dermatol. 2017 Dec 1;153(12):1256-1262. doi: 10.1001/jamadermatol.2017.3225.

PMID:
28914955
38.

Developing a protocol to identify and prioritize research questions for psoriasis: a James Lind Alliance Priority Setting Partnership.

Majeed-Ariss R, McPhee M, Bundy C, Griffiths CEM, Young H; Psoriasis Priority Setting Partnership Steering Group.

Br J Dermatol. 2018 Jun;178(6):1383-1387. doi: 10.1111/bjd.15992. Epub 2018 Mar 31.

PMID:
28906549
39.

Impact of Ixekizumab Treatment on Depressive Symptoms and Systemic Inflammation in Patients with Moderate-to-Severe Psoriasis: An Integrated Analysis of Three Phase 3 Clinical Studies.

Griffiths CEM, Fava M, Miller AH, Russell J, Ball SG, Xu W, Acharya N, Rapaport MH.

Psychother Psychosom. 2017;86(5):260-267. doi: 10.1159/000479163. Epub 2017 Sep 14.

40.

Inhibition of IL-17A by secukinumab shows no evidence of increased Mycobacterium tuberculosis infections.

Kammüller M, Tsai TF, Griffiths CE, Kapoor N, Kolattukudy PE, Brees D, Chibout SD, Safi J Jr, Fox T.

Clin Transl Immunology. 2017 Aug 25;6(8):e152. doi: 10.1038/cti.2017.34. eCollection 2017 Aug.

41.

A new in vitro assay to test UVR protection of dermal extracellular matrix components by a flat spectrum sunscreen.

Hibbert SA, Costello P, O'Connor C, Bell M, Griffiths CEM, Watson REB, Sherratt MJ.

J Photochem Photobiol B. 2017 Oct;175:58-64. doi: 10.1016/j.jphotobiol.2017.08.020. Epub 2017 Aug 16.

42.

Research Techniques Made Simple: Bioinformatics for Genome-Scale Biology.

Foulkes AC, Watson DS, Griffiths CEM, Warren RB, Huber W, Barnes MR.

J Invest Dermatol. 2017 Sep;137(9):e163-e168. doi: 10.1016/j.jid.2017.07.095. Review.

PMID:
28843296
43.

European Society for Dermatological Research (ESDR): Shifting Scope and Expanding Boundaries, Promoting Cutaneous Biology Research across Europe and beyond.

Schmuth M, Gilliet M, Griffiths CEM, Barker JN.

J Invest Dermatol. 2017 Sep;137(9):1817-1819. doi: 10.1016/j.jid.2017.07.821. No abstract available.

PMID:
28843291
44.

Lower levels of interleukin-1β gene expression are associated with impaired Langerhans' cell migration in aged human skin.

Pilkington SM, Ogden S, Eaton LH, Dearman RJ, Kimber I, Griffiths CEM.

Immunology. 2018 Jan;153(1):60-70. doi: 10.1111/imm.12810. Epub 2017 Aug 31.

45.

Measuring the societal impact of psoriasis in the United Kingdom through a non-interventional study of patients.

Griffiths CE, Williams R, Halliday AC, Leman JA.

J Eur Acad Dermatol Venereol. 2018 Jan;32(1):e5-e6. doi: 10.1111/jdv.14429. Epub 2017 Jul 16. No abstract available.

PMID:
28646610
46.

Medication non-adherence: the hidden problem in clinical practice.

Thorneloe RJ, Griffiths CEM, Cordingley L.

J Eur Acad Dermatol Venereol. 2017 Jun;31(6):923-924. doi: 10.1111/jdv.14324. No abstract available.

PMID:
28621501
47.

The association between psoriasis and coeliac disease.

Egeberg A, Griffiths CEM, Mallbris L, Gislason GH, Skov L.

Br J Dermatol. 2017 Dec;177(6):e329-e330. doi: 10.1111/bjd.15684. Epub 2017 Nov 24. No abstract available.

PMID:
28555725
48.

The global state of psoriasis disease epidemiology: a workshop report.

Griffiths CEM, van der Walt JM, Ashcroft DM, Flohr C, Naldi L, Nijsten T, Augustin M.

Br J Dermatol. 2017 Jul;177(1):e4-e7. doi: 10.1111/bjd.15610. Epub 2017 May 28.

49.

Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial.

Blauvelt A, de Bruin-Weller M, Gooderham M, Cather JC, Weisman J, Pariser D, Simpson EL, Papp KA, Hong HC, Rubel D, Foley P, Prens E, Griffiths CEM, Etoh T, Pinto PH, Pujol RM, Szepietowski JC, Ettler K, Kemény L, Zhu X, Akinlade B, Hultsch T, Mastey V, Gadkari A, Eckert L, Amin N, Graham NMH, Pirozzi G, Stahl N, Yancopoulos GD, Shumel B.

Lancet. 2017 Jun 10;389(10086):2287-2303. doi: 10.1016/S0140-6736(17)31191-1. Epub 2017 May 4.

PMID:
28478972
50.

'New to me': changing patient understanding of psoriasis and identifying mechanisms of change. The Pso Well® patient materials mixed-methods feasibility study.

Nelson PA, Kane K, Pearce CJ, Bundy C, Chisholm A, Hilton R, Thorneloe R, Young H, Griffiths CEM, Cordingley L; Identification and Management of Psoriasis-Associated Co morbidiTy (IMPACT) team.

Br J Dermatol. 2017 Sep;177(3):758-770. doi: 10.1111/bjd.15574. Epub 2017 Aug 17.

Supplemental Content

Loading ...
Support Center